Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Genetically Modified Herpes Virus to Treat Skin Cancer

By Drug Discovery Trends Editor | May 27, 2015

Microscopic view of herpes simplex virus (Credit: Nephron/ Licensed under CC by-SA 3.0 via Wikimedia)An experimental treatment using a genetically modified strain of the herpes simplex 1 virus has been shown to be effective in killing skin cancer cells and halting tumor growth, according to new research. The oncolytic virus immunotherapy, called T-VEC, was used to treat patients with melanoma in a Phase 3 clinical trial.

The research, published Tuesday in the Journal of Clinical Oncology, is the first to show this immunotherapy approach — in which a virus narrowly targets cancer cells and activates the immune system to fight cancer — significantly improved odds in the treatment of skin cancer tumors, especially inoperable ones.

The clinical trial was conducted across 64 research centers around the world and led by the Institute of Cancer Research (ICR) in London.

In a study of 436 patients with inoperable malignant melanoma, more than 16.3% of patients given talimogene laherparepvec — T-VEC, manufactured by Amgen — showed a lasting response for six months, compared with 2.1% of those in the control group given normal treatment. Some study participants had a response that went beyond three years.

“We may normally think of viruses as the enemies of mankind, but it’s their very ability to specifically infect and kill human cells that make them such promising cancer treatments, said Paul Workman, chief executive of the ICR, in a statement.

Patients with stage III and early stage IV melanoma injected with T-VEC therapy (163 people in total) lived an average of 41 months, compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy.

Scientists designed T-VEC by removing two key genes, which keep it from replicating within healthy cells. Instead, the treatment detects and attacks cancer cells. What’s more, T-VEC is genetically engineered to produce a molecule called granulocyte-macrophage colony stimulating factor (GM-CSF) — which activates the immune system to destroy tumors.

Cancer scientists are predicting this could be the first wave of indications for these cancer-fighting agents in the coming years.

“There is increasing excitement over the use of viral treatments, like T-VEC, because they can launch a two-pronged attack on tumors — both killing cancer cells directly and marshalling the immune system against them,” said Kevin Harrington, U.K. trial leader and professor of biological cancer therapies at the ICR, said in a statement. Harrington has been working on this particular virus for about a decade.

“And because viral treatment can target cancer cells specifically,” Harrington added, “it tends to have fewer side-effects than traditional chemotherapy or some of the other new immunotherapies.”

Rates of skin cancer have increased for the past 30 years, with more than 73,000 new cases of melanoma diagnosed this year and nearly 10,000 deaths, according to the American Cancer Society.

Responses to T-VEC were strongest in patients with less advanced cancers and in those who had not received any prior treatment, Harrington said. Because of this, T-VEC has potential as a first-line treatment for more advanced melanomas, according to the researchers.

Trials are also underway to determine how T-VEC might work with other cancers. “Now that oncolytic viruses have demonstrated an acceptable risk/benefit profile in melanoma, this treatment may be tested against other types of cancer where options are more limited,” said Howard L. Kaufman, M.D., associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey, who also collaborated on the research.

The drug, produced by Amgen, has been submitted to the U.S. Food and Drug Administration and the European Medicines Agency for approval.

 

Professor Kevin Harrington, U.K. trial leader, discusses the research in this video.

Source: The Institute of Cancer Research

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE